Form 4: GRI Bio CFO Leanne Kelly Acquires Stock Options

GRI Bio's Chief Financial Officer, Leanne Kelly, acquired 43,319 stock options at an exercise price of $0.6857 on January 23, 2025.

Summary

• Leanne Kelly, the Chief Financial Officer of GRI Bio, Inc., has acquired 43,319 stock options.
• The transaction occurred on January 23, 2025.
• The exercise price for these options is $0.6857 per share.
• The options become exercisable on January 23, 2025, and expire on January 23, 2035.
• These options are for the purchase of GRI Bio common stock.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment as it reports a standard stock option grant. It is neither particularly positive nor negative.

Positives

• The acquisition of stock options by the CFO could indicate confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders when they acquire or dispose of company securities. It is a routine part of corporate governance and transparency.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for executives in publicly traded companies, including those in the biotechnology sector like GRI Bio.
• The exercise price of $0.6857 is specific to GRI Bio's stock and its valuation at the time of the grant.
• The 10-year expiration period is a typical duration for stock options.

Stakeholder Impact

• The stock option grant could be viewed positively by shareholders as it aligns the CFO's interests with the company's performance.

Key Dates

Keywords

stock options, insider trading, GRI Bio, Leanne Kelly, CFO, equity, compensation